Legend Biotech Corp stock (US52490G1022): ASCO 2026 LB2102 data put early focus on solid tumor pipeline

Legend Biotech shares on Nasdaq traded moderately higher after the US cell therapy specialist presented first-in-human Phase 1 data for its DLL3-targeted CAR-T candidate LB2102 in small cell lung cancer and updated CARVYKTI findings at ASCO 2026.

Legend Biotech shares on the Nasdaq Global Select Market were in focus after the United States-based cell therapy company presented first-in-human Phase 1 results for its investigational DLL3-targeted CAR-T therapy LB2102 in relapsed or refractory small cell lung cancer and large-cell neuroendocrine carcinoma, alongside updated CARVYKTI data, at the ASCO 2026 meeting in Chicago.

According to a June 01, 2026 press release distributed via GlobeNewswire, the New Jersey-headquartered group reported that LB2102 showed early anti-tumor activity with a manageable safety profile in heavily pretreated patients, with an objective response rate of 20% and a disease control rate of 70% across all treated cohorts in the Phase 1 study.Legend Biotech press release as of 06/01/2026 The same disclosure noted that higher-dose cohorts achieved an objective response rate of up to 28.6% and disease control of 78.6%, with median duration of response reported at around 6.5 months and disease control lasting roughly 6.1 months, and no dose-limiting toxicities or treatment-related deaths observed.Legend Biotech investor information as of 06/01/2026

Beyond the new solid tumor data, the company also used its ASCO 2026 presence to share additional analyses from the CARTITUDE-4 study and commercial experience with CARVYKTI, the BCMA-directed CAR-T therapy co-developed with Johnson & Johnson for multiple myeloma, highlighting 30-month overall survival rates above 85% in certain subgroups and an incidence of IEC-associated enterocolitis of 1.2% in treated patients, according to the same communication.StockTitan summary as of 06/01/2026

The stock, which trades under the ticker LEGN in the United States, recently changed hands at around USD 27 on Nasdaq, giving Legend Biotech a market capitalization in the range of USD 4.8 billion, according to a contemporaneous analyst-rating recap that cited the latest quote and market cap figures.Investing.com analyst overview as of 05/31/2026 The trading venue and currency anchor the name in the US equity universe, while the cell therapy focus places it alongside other Nasdaq-listed biotechnology developers active in oncology.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Legend Biotech Corp
• Sector/industry: Biotechnology - cell and gene therapy, oncology
• Headquarters/country: Somerset, New Jersey, United States
• Core markets: North America, Europe and selected Asia-Pacific markets
• Key revenue drivers: BCMA-directed CAR-T therapy CARVYKTI and partnered milestones, with additional value potential from pipeline candidates such as LB2102 in solid tumors
• Home exchange/listing venue: Nasdaq Global Select Market (LEGN)
• Trading currency: USD

Legend Biotech Corp: core business model

Legend Biotech focuses on discovering, developing and commercializing cell-based immunotherapies, with revenue today largely underpinned by its partnered multiple myeloma product CARVYKTI and future growth tied to advancing a broader pipeline of autologous CAR-T candidates like LB2102 into later-stage trials and additional indications.

Latest quarterly results for Legend Biotech Corp at a glance

While the ASCO 2026 disclosures have shifted market attention toward Legend Biotech's clinical data and pipeline potential, the company also recently reported its latest set of quarterly financials, which provide context for its cash position and investment in research and development. According to the most recent Form 6-K filing and accompanying earnings release available via the investor relations website, Legend Biotech posted continued revenue growth driven by sales of CARVYKTI and collaboration-related income, while research and development expenses remained elevated as the company funded multiple CAR-T programs in oncology.Legend Biotech financial information as of 2026

Management highlighted in the same disclosure that cash, cash equivalents and short-term investments remained sufficient to support ongoing clinical programs and commercial activities for CARVYKTI over the near term, which is an important consideration when assessing the impact of new trial readouts such as the LB2102 Phase 1 data in small cell lung cancer and large-cell neuroendocrine carcinoma presented at ASCO 2026.TipRanks company announcement as of 06/01/2026

Conclusion

The ASCO 2026 update has put Legend Biotech's LB2102 candidate in the spotlight as an early but notable attempt to extend the reach of the company's cell therapy expertise into solid tumors, with Phase 1 data showing measurable responses and a manageable safety profile in heavily pretreated small cell lung cancer and large-cell neuroendocrine carcinoma. At the same time, reinforced CARTITUDE-4 findings and commercial safety statistics for CARVYKTI underline the role of multiple myeloma as the current financial backbone of the business, which in turn helps fund ongoing development work in new indications. How markets balance the promise of LB2102 against the execution risks inherent in solid tumor CAR-T development is likely to shape sentiment on the stock alongside upcoming financial results and further clinical milestones.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.